A low-dose of apatinib, a small molecule tyrosine kinase inhibitor, alleviates hypoxia, increases cluster of differentiation (CD)8+ T cell infiltration, and reduces tumor-related macrophage recruitment in murine lung cancer models. Here, CD8A is linked to neoplasm.